At a Glance
- Companies: Concept Life Sciences and OpenBench
- Focus area: AI-driven hit discovery
- Model: Success-based, capital-efficient services
- Technology: Structure-based AI + design-make-test platform
- Next steps: Deliver early-stage discovery programmes for clients
What happened?
Concept Life Sciences and OpenBench have formed a strategic partnership to offer AI-enabled hit discovery services. The collaboration combines OpenBench’s structure-based AI platform with Concept’s integrated “design-make-test” laboratory capabilities.
Why does it matter?
Early drug discovery is costly and high risk, particularly for smaller biotech companies. A success-based model could reduce upfront costs and align incentives, making it easier for companies to access advanced AI-driven discovery without heavy infrastructure investment.
Who’s behind it?
Concept Life Sciences is a UK-based contract research organisation providing integrated discovery and development services. OpenBench specialises in structure-based AI for identifying and optimising drug candidates.
How was it achieved?
The partnership integrates computational and experimental workflows. OpenBench’s AI models generate and prioritise candidate molecules based on structural biology, while Concept executes synthesis and testing to validate hits in a closed-loop system.
What’s next?
The companies plan to offer the combined platform to biotech and pharma clients, focusing on early-stage programmes. If successful, the model could expand into broader discovery services and longer-term partnerships.